AMRN Stock Recent News

After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.

Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter L.

-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months --  -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market --

AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.

DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET.

MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.